JUNO +24%/PM on resumption of interrupted phase-2 trial—without fludarabine: http://finance.yahoo.com/news/juno-therapeutics-resume-jcar015-phase-205000686.html Under the revised protocol, the ROCKET trial will continue enrollment using JCAR015 with cyclophosphamide pre-conditioning only.